Is taking Venetoclax for 14 days a course of treatment?
Venetoclax (Venetoclax) is currently widely used to treat elderly acute myeloid leukemia (AML) who are not suitable for intensive remission induction therapy. Prolonged myelosuppression, increased incidence of infection, and prolonged hospitalization are major concerns in cases treated with venetoclax. The clinical case study studied 13 patients with newly diagnosed AML who received induction therapy with venetoclax + azacitidine (AZA).
Eight patients received intravenous infusion for 14 days (Ven14 group), and five patients received intravenous infusion for 28 days (Ven28 group). Comprehensive complete response (CRc) rate was 76.9% in total, and the CRc rates of Ven14 group and Ven28 group were almost the same (75.0% and 80.0% respectively). The median overall survival (OS) was not reached in the Ven14 group and was 254 days in the Ven28 group. The median event-free survival (EFS) was not reached in the Ven4 group and was 178 days in the Ven28 group. Compared with the Ven28 group, the Ven14 group may have the potential to reduce febrile neutropenia (37.5% vs. 80%) and shorten the length of hospital stay. Ven14 has the same CRc rate and survival rate, a better safety profile, and shorter hospital stay than Ven28. However, the specific time and course of treatment for patients to take Venekra needs to be determined by the doctor.
The original drug of Venacla is already on the market in China, and can be found in the Category B medical insurance directory. The specification is 100mg*14 tablets and the price per box may be around RMB 5,000. The Turkish version of Venaclaoriginal drug, specifications100mg*112 tablets, sold overseas, costs around RMB 10,000 per box (the price may fluctuate due to exchange rates), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)